Innate Pharma S.A. (IPHA)
Market Cap | 352.17M |
Revenue (ttm) | 96.42M |
Net Income (ttm) | -23.32M |
Shares Out | 74.71M |
EPS (ttm) | -0.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 15 |
Last Price | $4.44 |
Previous Close | $4.59 |
Change ($) | -0.15 |
Change (%) | -3.27% |
Day's Open | 4.60 |
Day's Range | 4.44 - 4.59 |
Day's Volume | 659 |
52-Week Range | 3.77 - 8.20 |
MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made ...
Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the deci...
MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its s...
Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior ma...
New York, New York--(Newsfile Corp. - December 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate"...
Innate Pharma, S.A.: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information Investors with losses are encouraged to contact the firm before Decemb...
LOS ANGELES, Dec. 21, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. ("Innat...
New York, New York--(Newsfile Corp. - December 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA...
New York, New York--(Newsfile Corp. - December 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the ...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class ...
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...
BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action fil...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are ...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 1...
MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return t...
Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US an...
New York, New York--(Newsfile Corp. - December 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between...
LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class act...
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: I...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are ad...
New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advised...
MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial cal...
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and S...
LOS ANGELES, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class act...
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: I...
New York, New York--(Newsfile Corp. - November 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
Marseille, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash positio...
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...
Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Priority Medicines (PRIME) designation supports...
MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its ...
New York, New York--(Newsfile Corp. - November 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
New York, New York--(Newsfile Corp. - November 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...
New York, New York--(Newsfile Corp. - November 6, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" ...
BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA...
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...
BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Innate Pharma SA (IPHA) Inv...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or o...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray, Leading Securities Fraud Law Firm, Announces Filing of Securities Class Action on Behalf of Innate Pharma SA (IPHA...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz announces an investigation of Innate Pharma SA (“Innate” or the “Company”) (NASDAQ: IPHA) on behalf of inv...
BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, ...
SAN DIEGO and MARSEILLE, France, Oct. 27, 2020 /PRNewswire/ -- Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Innate Pharma S.A...
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advise...
About IPHA
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the trea... [Read more...]
Industry Biotechnology | IPO Date Oct 17, 2019 |
CEO Mondher Mahjoubi | Employees 247 |
Stock Exchange NASDAQ | Ticker Symbol IPHA |
Analyst Forecasts
According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 6.31, which is an increase of 42.12% from the latest price.